New: 2021 EULAR Recommendations for lifestyle and work in people with RMDs

This is the lay version of the 2021 EULAR recommendations for lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. The original publication can be downloaded from the EULAR website: www.eular.org. Gwinnutt JM, et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal […]

Read More…

Cardiovascular risk management in rheumatic diseases

This is the lay version of the EULAR recommendations for managing cardiovascular risks in people with rheumatic and musculoskeletal diseases. The original publication can be downloaded from the EULAR website: www.eular.org. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and […]

Read More…

Updated: COVID-19 vaccination recommendations in RMDs

This is the lay version of the EULAR recommendations for COVID-19 vaccination in people with rheumatic and musculoskeletal diseases. The original publication can be downloaded from the EULAR website: www.eular.org. Landewé RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context […]

Read More…

COVID vaccination in people with rheumatic and musculoskeletal diseases

This is the lay version of a paper describing the safety of COVID-19 vaccination based on data from the COVAX registry. The original publication can be downloaded from the following link: Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR […]

Read More…

Update: Using rheumatology drugs for COVID-19

This is the lay version of the EULAR points to consider on the use of medicines traditionally used in rheumatology to treat the inflammation seen in people with severe COVID-19. The original publication can be downloaded from the EULAR website: www.eular.org. Alunno A, et al. 2021 update of the EULAR points to consider on the […]

Read More…

Managing difficult-to-treat arthritis

This is the lay version of the EULAR points to consider on the management of people with difficult-to-treat rheumatoid arthritis. The original publication can be downloaded from the EULAR website: www.eular.org. Nagy G, et al. EULAR points to consider for the management of difficult-to-treat arthritis. Ann Rheum Dis doi:10.1136/annrheumdis-2021-220973 Introduction EULAR recommendations give advice to […]

Read More…

New QIs help assess and improve care in Lupus

Quality indicators can help clinics to implement the EULAR recommendations in everyday care INTRODUCTION Systemic lupus erythematosus (often called Lupus or SLE) is an autoimmune disease. It typically starts in women between the ages of 15 and 45. Lupus symptoms can vary from patient to patient. People with Lupus are often very tired, have joint […]

Read More…

Self-managing your inflammatory arthritis

This is the lay version of the EULAR recommendations for self-management in people with types of inflammatory arthritis. The original publication can be downloaded from the EULAR website: www.eular.org. Nikiphorou E, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis 2021;0:1-8. doi:10.1136/annrheumdis-2021-220249 Introduction EULAR recommendations […]

Read More…

COVID-19-related death in rheumatic diseases

This is the lay version of a paper published on behalf of the COVID-19 Global Rheumatology Alliance Consortium. It examines COVID-19-related death in people with rheumatic diseases. The original publication can be downloaded from the EULAR website: www.eular.org. Strangfeld A, et al. Factors Associated with COVID-19-related Death in People with Rheumatic Diseases: Results from the […]

Read More…

Managing irAEs with checkpoint inhibitors

This is the lay version of the EULAR ‘points to consider’ for the diagnosis and management of rheumatic immune-related side effects in people taking checkpoint inhibitors for cancer. The original publication can be downloaded from the EULAR website: www.eular.org. Kostine M, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related […]

Read More…